Janet Dancey

Dr. Janet Dancey is a Professor in the Department of Oncology at Queen's University and Director of the Canadian Cancer Trials Group (CCTG). She holds key appointments as Attending Staff at Kingston General Hospital and Hotel Dieu, and as Program Leader for High Impact Clinical Trials at the Ontario Institute for Cancer Research. Her clinical focus is on gastrointestinal cancers, with expertise in translational research, experimental therapeutics, and clinical trial methodology. Dr. Dancey leads initiatives such as the Melanoma Disease Site Committee at CCTG and chairs the CCO-OICR Experimental Therapeutics and Translational Research Network. Her research emphasizes Phase I/II trials, pharmacodynamic marker development, and genomics-driven approaches to cancer therapy. She has pioneered efforts to improve clinical trial accessibility through frameworks like CRAFT (Canadian Remote Access Framework for Clinical Trials) and contributed to global oncology initiatives such as the Marathon of Hope Cancer Centres Network. Her work addresses barriers to trial participation, including strategies for community cancer centers and rare cancer populations.

Dr. Dancey’s academic contributions span over 150 peer-reviewed articles, focusing on biomarker-driven therapies, immunotherapy combinations, and adaptive trial designs. She advocates for standardized response criteria (e.g., iRECIST) and collaborates internationally to advance precision oncology. Her educational efforts include training clinician scientists in clinical trial design and implementation, ensuring rigorous methodological standards in oncology research.